CJC-1295 (no DAC), GHRP-2 10mg (Blend) is a peptide-based research formulation intended for laboratory investigation of growth hormone (GH) regulatory mechanisms. This blend combines a short-acting growth hormone–releasing hormone (GHRH) analogue with a growth hormone secretagogue receptor (GHSR) agonist to support mechanistic studies of dual-receptor signaling within the anterior pituitary.

All information presented is limited strictly to in-vitro experimentation and in-vivo animal research contexts and is intended exclusively for basic scientific investigation.

CJC-1295 (no DAC) is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) that does not incorporate a Drug Affinity Complex (DAC) or any albumin-binding moiety. This peptide is therefore studied as a short-acting GHRH analogue with biochemical properties closer to native GHRH, while exhibiting modified resistance to enzymatic degradation under experimental conditions.

GHRP-2 is a synthetic peptide that interacts with the growth hormone secretagogue receptor (GHSR-1a), activating intracellular signaling pathways distinct from those associated with GHRH receptor engagement. In blended formulations, these peptides serve as complementary molecular probes for receptor-specific signaling analysis.

This peptide blend is used in preclinical research to examine pulsatile GH secretion patterns, receptor activation timing, and coordination between GHRH and GHSR signaling pathways. Experimental systems include isolated pituitary tissues and animal models utilized to study endocrine signal integration.

Additional applications include investigation of downstream signaling events, transcriptional regulation, and second-messenger dynamics associated with somatotroph cell activation under controlled laboratory conditions.

CJC-1295 (no DAC) binds to the GHRH receptor on pituitary somatotroph cells, stimulating adenylate cyclase activity and increasing intracellular cyclic AMP (cAMP) levels. This pathway is associated with transcriptional regulation and vesicular processes involved in GH secretion.

GHRP-2 activates the GHSR-1a receptor, initiating phospholipase C–dependent signaling, inositol triphosphate generation, and intracellular calcium mobilization. Combined pathway activation is studied to assess receptor cross-talk and signaling convergence in preclinical systems.

Published preclinical studies involving GHRH analogues and GHSR agonists have examined GH secretion dynamics, receptor activity, and associated molecular markers in animal models. Observations are reported within controlled laboratory environments.

All findings are interpreted strictly within the scope of basic research and do not imply any clinical, diagnostic, or applied outcomes.

This blended peptide formulation is supplied in a lyophilized form suitable for laboratory handling and analytical evaluation. Identity and purity are characterized using high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to support consistency and reproducibility in research applications.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [7] under the referenced citations.

1. M. Ionescu and L. A. Frohman, “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog,” J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]
2. D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]
3. V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [PubMed]
4. D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]
5. S. L. Teichman, A. Neale, B. Lawrence, C. Gagnon, J.-P. Castaigne, and L. A. Frohman, “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults,” J. Clin. Endocrinol. Metab., vol. 91, no. 3, pp. 799–805, Mar. 2006. [PubMed]
6. B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006. [PMC]
7.  Jetté, Lucie & Leger, Roger & Thibaudeau, Karen & Benquet, Corinne & Robitaille, Martin & Pellerin, Isabelle & Paradis, Véronique & Wyk, Pieter & Pham, Khan & Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.